537 related articles for article (PubMed ID: 25525179)
41. Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.
Fei G; Raehal K; Liu S; Qu MH; Sun X; Wang GD; Wang XY; Xia Y; Schmid CL; Bohn LM; Wood JD
J Pharmacol Exp Ther; 2010 Jul; 334(1):333-40. PubMed ID: 20406855
[TBL] [Abstract][Full Text] [Related]
42. Distal Colon Motor Dysfunction in Mice with Chronic Kidney Disease: Putative Role of Uremic Toxins.
Hoibian E; Florens N; Koppe L; Vidal H; Soulage CO
Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29772737
[TBL] [Abstract][Full Text] [Related]
43. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents.
Wang X; Yang S; Li S; Zhao L; Hao Y; Qin J; Zhang L; Zhang C; Bian W; Zuo L; Gao X; Zhu B; Lei XG; Gu Z; Cui W; Xu X; Li Z; Zhu B; Li Y; Chen S; Guo H; Zhang H; Sun J; Zhang M; Hui Y; Zhang X; Liu X; Sun B; Wang L; Qiu Q; Zhang Y; Li X; Liu W; Xue R; Wu H; Shao D; Li J; Zhou Y; Li S; Yang R; Pedersen OB; Yu Z; Ehrlich SD; Ren F
Gut; 2020 Dec; 69(12):2131-2142. PubMed ID: 32241904
[TBL] [Abstract][Full Text] [Related]
44. Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota.
Musch MW; Wang Y; Claud EC; Chang EB
Dig Dis Sci; 2013 Mar; 58(3):668-77. PubMed ID: 23329012
[TBL] [Abstract][Full Text] [Related]
45. Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies.
Pan W; Kang Y
Int Urol Nephrol; 2018 Feb; 50(2):289-299. PubMed ID: 28849345
[TBL] [Abstract][Full Text] [Related]
46. Chronic kidney disease after 5/6 nephrectomy disturbs the intestinal microbiota and alters intestinal motility.
Nishiyama K; Aono K; Fujimoto Y; Kuwamura M; Okada T; Tokumoto H; Izawa T; Okano R; Nakajima H; Takeuchi T; Azuma YT
J Cell Physiol; 2019 May; 234(5):6667-6678. PubMed ID: 30317589
[TBL] [Abstract][Full Text] [Related]
47. Lubiprostone: a novel treatment for chronic constipation.
Lacy BE; Levy LC
Clin Interv Aging; 2008; 3(2):357-64. PubMed ID: 18686757
[TBL] [Abstract][Full Text] [Related]
48. Oral iron supplementation: Potential implications for the gut microbiome and metabolome in patients with CKD.
Kortman GAM; Reijnders D; Swinkels DW
Hemodial Int; 2017 Jun; 21 Suppl 1():S28-S36. PubMed ID: 28328083
[TBL] [Abstract][Full Text] [Related]
49. The gut microbiome, kidney disease, and targeted interventions.
Ramezani A; Raj DS
J Am Soc Nephrol; 2014 Apr; 25(4):657-70. PubMed ID: 24231662
[TBL] [Abstract][Full Text] [Related]
50. The Role of the Gut Microbiome on Chronic Kidney Disease.
Sampaio-Maia B; Simões-Silva L; Pestana M; Araujo R; Soares-Silva IJ
Adv Appl Microbiol; 2016; 96():65-94. PubMed ID: 27565581
[TBL] [Abstract][Full Text] [Related]
51. Link between gut microbiota dysbiosis and chronic kidney disease.
Noce A; Marchetti M; Marrone G; Di Renzo L; Di Lauro M; Di Daniele F; Albanese M; Di Daniele N; De Lorenzo A
Eur Rev Med Pharmacol Sci; 2022 Mar; 26(6):2057-2074. PubMed ID: 35363356
[TBL] [Abstract][Full Text] [Related]
52. Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease.
Prokopienko AJ; Nolin TD
Expert Rev Clin Pharmacol; 2018 Jan; 11(1):71-82. PubMed ID: 28905671
[TBL] [Abstract][Full Text] [Related]
53. The impact of gut microbiota on kidney function and pathogenesis.
Mahmoodpoor F; Rahbar Saadat Y; Barzegari A; Ardalan M; Zununi Vahed S
Biomed Pharmacother; 2017 Sep; 93():412-419. PubMed ID: 28654798
[TBL] [Abstract][Full Text] [Related]
54. Homeostasis in the Gut Microbiota in Chronic Kidney Disease.
Bhargava S; Merckelbach E; Noels H; Vohra A; Jankowski J
Toxins (Basel); 2022 Sep; 14(10):. PubMed ID: 36287917
[TBL] [Abstract][Full Text] [Related]
55. Oat Dietary Fiber Delays the Progression of Chronic Kidney Disease in Mice by Modulating the Gut Microbiota and Reducing Uremic Toxin Levels.
Xia J; Zhang Y; Zhang S; Lu C; Huan H; Guan X
J Agric Food Chem; 2024 Jun; ():. PubMed ID: 38836841
[TBL] [Abstract][Full Text] [Related]
56. Alteration of the gut microbiota by vinegar is associated with amelioration of hyperoxaluria-induced kidney injury.
Zhu W; Liu Y; Duan X; Xiao C; Lan Y; Luo L; Wu C; Yang Z; Mai X; Lu S; Zhong W; Li S; He Z; Zhang X; Liu Y; Zeng G
Food Funct; 2020 Mar; 11(3):2639-2653. PubMed ID: 32159193
[TBL] [Abstract][Full Text] [Related]
57. Gut Microbiota and Cardiovascular Uremic Toxicities.
Velasquez MT; Centron P; Barrows I; Dwivedi R; Raj DS
Toxins (Basel); 2018 Jul; 10(7):. PubMed ID: 29997362
[TBL] [Abstract][Full Text] [Related]
58. Effects of the oral adsorbent AST-120 on fecal p-cresol and indole levels and on the gut microbiota composition.
Sato E; Hosomi K; Sekimoto A; Mishima E; Oe Y; Saigusa D; Ito S; Abe T; Sato H; Kunisawa J; Niwa T; Takahashi N
Biochem Biophys Res Commun; 2020 May; 525(3):773-779. PubMed ID: 32147096
[TBL] [Abstract][Full Text] [Related]
59. Gut microbiota in chronic kidney disease.
Cigarran Guldris S; González Parra E; Cases Amenós A
Nefrologia; 2017; 37(1):9-19. PubMed ID: 27553986
[TBL] [Abstract][Full Text] [Related]
60. An Innovative Synbiotic Formulation Decreases Free Serum Indoxyl Sulfate, Small Intestine Permeability and Ameliorates Gastrointestinal Symptoms in a Randomized Pilot Trial in Stage IIIb-IV CKD Patients.
Cosola C; Rocchetti MT; di Bari I; Acquaviva PM; Maranzano V; Corciulo S; Di Ciaula A; Di Palo DM; La Forgia FM; Fontana S; De Angelis M; Portincasa P; Gesualdo L
Toxins (Basel); 2021 May; 13(5):. PubMed ID: 34063068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
